Research programme: coagulation factor modulators - Aronora

Drug Profile

Research programme: coagulation factor modulators - Aronora

Alternative Names: AB-002; AB-012; AB-022; AXIMAB; EWE-thrombin; Mab 14E11 - Aronora; ProCase; WE-thrombin; XISOMAB; Xisomab 3G3

Latest Information Update: 28 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Oregon Health & Science University; Washington University
  • Developer Aronora; Oregon Health & Science University; Washington University
  • Class Enzymes; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Factor IX inhibitors; Factor XI inhibitors; Factor XIIa inhibitors; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Sepsis; Venous thrombosis

Most Recent Events

  • 05 Apr 2017 Aronora plans a phase I trial of xisomab for Thrombosis (In volunteers) (NCT03097341)
  • 01 Jun 2010 Preclinical trials in Sepsis in USA (Parenteral)
  • 01 Jan 2007 Preclinical trials in Venous thrombosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top